In our study, we evaluated the safety and efficacy of Brentuximab vedotin (BV) with or without the addition of donor lymphocyte infusion (DLI) after allogeneic stem cell transplantation (allo-SCT) in 16 patients with advanced Hodgkin lymphoma (HL). Thirteen patients with relapsed HL after allo-SCT received BV as treatment for active disease. Three patients without progression of HL after allo-SCT received BV as consolidation. Twelve patients had been previously exposed to BV for treatment of relapse after autologous-SCT. Ten out of 16 patients received BV in combination with DLI. Among the 13 patients treated for active disease, CR and PR was observed in 7 and 2 patients, respectively. With a median follow-up of 13 months, 13 out of 16 patients are alive, while 3 died because of disease progression. The median PFS was 6 months. DLI-associated GVHD occurred in seven patients. Five patients with GVHD required immunosuppression, and in all cases, GVHD resolved after a short course of low dose steroids, implying that an anti-GVHD modulating effect could be induced by the concurrent administration of BV. No serious adverse event was observed in any of the patients.
INTRODUCTION
Brentuximab vedotin (BV) consists of an anti-CD30 monoclonal Ab conjugated to the agent monomethyl auristatin E, which disrupts the microtubule system leading to cell apoptosis. BV was tested in a phase 2 trial including 102 Hodgkin lymphoma (HL) patients who had relapsed after a previous autologous stem cell transplantation (auto-SCT). The overall response rate was 75% with 34% of patients achieving CR. 1 Patients with HL who progress after auto-SCT have a dismal prognosis. Therapeutic efficacy of conventional chemoradiotherapy is of little benefit and only allogeneic stem cell transplantation (allo-SCT) is associated with prolonged PFS and overall survival in a proportion of eligible patients. 2 However, the relapse rate after allo-SCT is approximately 40-50% and long-term PFS is less than 40%, mostly owing to the fact that patients with HL referred to allo-SCT are usually heavily pretreated or are in a state of chemo-refractoriness. 3 Theoretically, improvement of results may be achieved by using consolidation or maintenance treatment. BV offers a unique opportunity to be administered as maintenance therapy after allo-SCT to reduce relapse rate and tumor progression and to improve PFS.
Of note, there is a paucity of data regarding the efficacy and safety of BV, alone or in combination with donor lymphocyte infusion (DLI), for the treatment or prevention of relapse after allo-SCT.
In the present article, we present our experience of using this approach in a cohort of 16 patients.
METHODS
A search in the data set of the four participating transplant centers was performed with the aim of identifying patients with HL who received BV with or without DLI after allo-SCT. The objective of our study was to evaluate the safety and efficacy of BV as a single agent or in combination with DLI when administered after allo-SCT either as treatment for relapsed HL or as consolidation for high risk disease. A total of 45 patients with HL underwent allo-SCT during the last 5 years in the participating transplant centers, and 26 out of these 45 patients relapsed after transplant. Among them, we identified 16 patients who fulfilled the above criteria and were included in the analysis. Reasons for BV administration for treatment of relapse were drug availability and choice of treating physician. All patients gave written informed consent.
Response assessment was performed by using total body computed tomography and positron emission tomography scans according to recently revised criteria. 4 Regarding positron emission tomography scans, residual fluorodeoxyglucose (FDG) uptake of ⩽ 3 points of Deauville scale was considered complete metabolic response.
RESULTS

Patients
There were eight male and eight female patients, with a median age of 28 years (range, 15-40). Fourteen out of 16 patients had Hodgkin: brentuximab after allogeneic transplant P Tsirigotis et al Hodgkin: brentuximab after allogeneic transplant P Tsirigotis et al previously failed an auto-SCT. Twelve patients had previously received BV and five responded to treatment. Eleven patients had chemo-sensitive disease at the time of allo-SCT. The graft source was un-manipulated PBSCs from a matched related, a matched unrelated and 1-locus mismatched unrelated donor in eight, five and one patient, respectively. One patient received bone marrow from a matched related donor, while one patient received a double umbilical cord blood graft.
The best response to allo-SCT was as follows: eight and four patients achieved CR and PR, respectively, while four patients did not achieve an objective response.
Thirteen patients progressed in a median of 7 months (range, 2-17) after allo-SCT, and received BV as treatment for active disease (patient no. = 1 to 13 in Tables 1 and 2 ). Two patients in PR on day +100 after allo-SCT received BV as consolidation with the intention of improving the quality of remission (patient no. = 14 and 15 in Tables 1 and 2 ). One patient in CR on day +100 after allo-SCT received BV as maintenance with the aim of preventing disease progression (patient no. = 16 in Tables 1 and 2 ). Patient's characteristics are shown in Table 1 .
Treatment
All patients were planned to receive BV at a dose of 1.8 mg/kg every 3 weeks for a maximum of 8 or 12 cycles (12 patients previously exposed to BV were scheduled to receive a maximum of 8 BV doses) or till disease progression or toxicity. Two patients received chemotherapy before BV. A median of 4 (range, 2-16) BV cycles were administered. DLI was co-administered in 10 out of 15 patients (excluding 1 patient who received double umbilical cord blood graft). Decision for DLI was at the discretion of the treating physician. Three patients did not receive DLI owing to the treating physician's choice, while two did not receive DLI owing to active GVHD at the time of planned BV administration. The number of DLIs and the doses are shown in Table 2 . At the last follow-up, three patients in CR and one in PR are still under treatment with BV.
Response to treatment and survival Nine out of 13 patients treated with BV after allo-SCT for disease progression had an objective response. In more detail, seven and two patients achieved CR and PR, respectively. Two out of two patients in PR after allo-SCT received BV as consolidation and both achieved CR. In total, 11 out of 15 patients had an objective response to treatment for an overall response rate of 73%. One patient in CR after allo-SCT who received BV as maintenance is in continuous CR and still under treatment.
After treatment with BV with or without DLI, disease progression was observed in eight patients in a median of 5.5 months (range, 4-10), while eight patients remain progressionfree with a median follow-up of 9 months (range, 2-43) after the first infusion of BV. After a median follow-up of 13 months (range, 2-47), 13 patients are still alive, while 3 died because of disease progression. Treatment outcome is shown in detail in Table 2 .
Subgroup of patients previously refractory to BV Notably, all seven patients who were previously refractory to BV (when administered after auto-SCT) responded to re-treatment with BV after allo-SCT. The best response was CR and PR in six and one patient, respectively. Three out of seven patients received BV as single agent, while four patients received BV in combination with DLI. Five out of seven patients are in continuous CR after a median follow-up period of 4 months, (range, 3-43 months). Toxicity BV/DLI treatment was well tolerated and no serious adverse effect was observed in any of the patients. Grade 1 diarrhea occurred in one patient, while two patients developed low grade fever after each cycle of BV. Grade 2 neutropenia and grade 2 thrombocytopenia developed in two and one patient post treatment with BV, respectively. In all patients, spontaneous recovery of blood counts occurred before the next administration of BV. Only one patient discontinued BV treatment because of occurrence of grade 2 peripheral neuropathy. No patient developed CMV disease or any other serious infection requiring hospitalization during treatment. CMV reactivation occurred in one patient who was concomitantly treated with low dose steroids for active GVHD. The CMV reactivation resolved with valganciclovir administration. All patients remained in a status of complete donor chimerism that was not affected by treatment with BV. Adverse events related to BV are shown in Table 3 .
Graft versus host disease GVHD developed in seven out of 10 patients post DLI administration. In more detail, acute GVHD of the skin (grade I) and intestine (grade 2) developed in one patient each. Mild chronic GVHD not requiring treatment was observed in two patients, while severe chronic GVHD developed in two patients. Of note is the observation that GVHD resolved in all five cases requiring treatment after a short course of low dose steroids. One patient with pre-existing chronic GVHD received repeated doses (10 7 /kg, 10 8 /kg) of DLI in combination with BV, without deterioration. On the contrary, complete resolution of chronic GVHD was observed 4 months after the last DLI infusion in this patient (no. = 8). At last follow-up, none of the patients had active GVHD requiring treatment. None of the six patients who received BV as single agent developed any clinical or laboratory sign of acute or chronic GVHD.
DISCUSSION
Administration of BV post allo-SCT to 16 very high risk and heavily pretreated HL patients resulted in an objective response rate of 73%. This high efficacy rate should not be attributed to BV alone but rather to the combination of BV with DLI, because we observed 9 responders among 10 patients treated with the combination. Treatment was well tolerated with no serious adverse events occurring in any of the patients. Abbreviation: BV = brentuximab vedotin. a Common Terminology Criteria for Adverse Events v3.0 (CTCAE) was used for grading of severity.
Hodgkin: brentuximab after allogeneic transplant P Tsirigotis et al
There is a paucity of data regarding post allo-SCT administration of BV. The safety and efficacy of BV after allo-SCT has been evaluated in a prospective trial including 25 BV-naive patients with recurrent HL. Toxicity was minimal and easily manageable, while the overall response and the CR rate were 50% and 38%, respectively. The median PFS was 7.8 months while the median overall survival was not reached at the time of publication. 5 In another trial, 16 previously BV-naive patients with HL relapsing after allo-SCT were included in a compassionate use program. Treatment was safe with anemia, neutropenia, thrombocytopenia and peripheral sensory neuropathy being reported as the most frequent side effects. The overall response rate was 69%, with five patients achieving CR. The median PFS and overall survival were 7 and 25 months, respectively. 6 Both the association of chronic GVHD with reduced incidence of relapse, as well as the efficacy of DLI to induce remissions in patients with HL relapsed after allo-SCT, support the concept of a graft versus Hodgkin effect. 7, 8 The largest body of data regarding the efficacy of DLI in patients with HL comes from the UK cooperative group trial. Seventy-six consecutive patients with relapsed/refractory HL underwent allo-SCT following a reduced intensity conditioning (RIC) consisting of fludarabine, melphalan and high dose Campath as a means of in vivo T-cell depletion. DLI was effective in reverting mixed to complete donor chimerism in 86% of the patients. Durable response to DLI was observed in 79% of patients treated for relapse, while the DLI-related mortality at 3 years was 7% and it was mainly attributed to GVHD. 9 However, it should be emphasized that these results have not been reproduced by other studies evaluating the efficacy of DLI to treat progressive or relapsed HL disease after allo-SCT. In these trials, responses to DLI were inconsistent and short-lived with no patient achieving long-term PFS. [10] [11] [12] We administered repeatedly high doses of CD3+ cells. The median dose administered was 10 7 CD3+ per kilogram. In our study, acute GVHD grade II occurred in two patients, while severe chronic GVHD occurred in only two patients. Importantly, GVHD resolved rapidly after a short course of low dose steroids. One patient with pre-existing chronic GVHD received repeated doses of DLI in combination with BV without any deterioration. No death associated with DLI was observed. The low severity of GVHD observed in the current study may be due to an immunemodulating effect produced by BV. Moreover, none of the six patients who received BV as single agent developed acute or chronic GVHD during follow-up, and this observation is also suggestive of a possible anti-GVHD effect. Previous studies have shown that CD30 is expressed on the surface of activated T cells present in inflammatory infiltrates of GVHD lesions. 13 Therefore, elimination of alloreactive CD30+ donor T cells induced by BV may result in decreased incidence and severity of GVHD. This possible effect of BV deserves further testing in prospective trials.
In the current study, we evaluated the efficacy and safety of BV in combination with DLI (n = 10) in 16 patients with advanced heavily pretreated HL after allo-SCT. Twelve patients had previously received BV for treatment of relapse after auto-SCT. We observed that administration of BV with DLI was effective while toxicity was minimal. Notably, re-administration of BV to patients previously treated for post auto-SCT relapse did not result in additional toxicity or resistance. Furthermore, BV combined with DLI yielded anti-tumor response in 9 out of 10 very high risk patients. The high success rate of the combination is highly suggestive of a possible synergistic effect. Of note is the observation that all seven patients who were refractory to BV post auto-SCT, responded to re-administration of BV post allo-SCT. Our observations are in accordance with the results of a previous report, showing that BV plus DLI after allo-SCT creates a vaccination like-effect against HL. 14 In conclusion, BV administration in combination with DLI is safe and induces significant anti-HL activity. Moreover, it is highly suggested that an immune-modulating effect induced by BV resulted in reduced incidence and severity of DLI-associated GVHD. The combination of BV plus DLI should be tested prospectively in larger number of patients with high risk HL after allo-SCT. It is conceivable that this approach will be more effective when used as consolidation of HL responding to allo-SCT rather than as treatment of an established relapse or progressive disease post allo-SCT.
